ALS Drugs: FDA Panel Weighed Less-Than-Ideal Data Against Amylyx’s Ability To Set Postapproval Price

Pill container with money
Some advisory committee members worried about giving Amylyx free rein to price its ALS drug based on suboptimal data. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers